AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03113227 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal examination
Description: Vaginal examination will be done for assessment of Bishop score
Study NCT00154258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Study NCT01887795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study NCT01887795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WBRT
Study NCT00494013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Protamine Suspension
Description: Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
Study NCT00494013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir
Description: Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
Study NCT00882219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xience V®
Description: Placement of a Xience V® stent within a restenosed bare metal stent.
Study NCT00737464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: iv (120, 200 or 360 micrograms) every 4 weeks for 12 weeks.
Study NCT02827565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA
Description: 10 ml blood sample
Study NCT03703570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: Oral administration
Study NCT03703570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study NCT03867916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation Program
Description: Use patient navigation program
Study NCT03867916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03867916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03212651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg IV infusion
Study NCT03807193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-selected treatment
Description: The participants will select their own treatment material with the help of a written manual. The interventions possible to choose are all interventions used in standard cognitive behavior therapy for anxiety and depression.
Study NCT03807193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Predetermined treatment
Description: The participants will be given a treatment program designed to address worry and generalized anxiety disorder. The program are based on newer forms of cognitive behavior therapy and include mindfulness and acceptance.
Study NCT03807193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly support
Description: The participants will have scheduled weekly support, once a week, during the treatment. The support till be delivered by students in clinical psychology.
Study NCT03807193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support on demand
Description: The participants will have support if and when they ask for it by themselves. If asked for the support will be delivered by students in clinical psychology.
Study NCT02303340 — intervention group
Intervention type: RADIATION
Intervention: Dual Energy X-ray Absorptiometry
Study NCT02691494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Estradiol/Norethindrone Acetate
Description: Placebo capsules
Study NCT02691494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/Norethindrone Acetate
Description: Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
Study NCT02856919 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: brimonidine tartrate
Description: Mirvaso® gel (5 mg/g brimonidine tartrate)
Study NCT02691494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Elagolix
Description: Film-coated placebo tablets
Study NCT02142829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL
Study NCT01749085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913, ketoconazole
Description: Subjects receive a 200 mg oral dose of PF-04449913 under fasted conditions with washout, then single 200 mg oral dose of PF-04449913 under fed with washout and finally a single 200 mg dose 0f PF-04449913 following dosing to steady state with ketoconazole
Study NCT01749085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913, ketoconazole
Description: Subjects receive a 200 mg oral dose of PF-04449913 under fed conditions with washout, then single 200 mg oral dose of PF-04449913 under fasted with washout and finally a single 200 mg dose of PF-04449913 following dosing to steady state with ketoconazole
Study NCT02142829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: On-Q Pain Ball
Description: bupivacaine HCl 0.25%
Study NCT03357497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very early mobilization
Description: The patient will be mobilized by a physiotherapist in our postoperative care unit. The intervention uses the SOMS protocol.
Study NCT03086876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level 4 Stepping Stones Triple P (SSTP)
Description: Stepping Stones Triple P is a system of psychoeducational and behavioural approaches to parenting a child with LD and challenging behaviour that aims to increase parental confidence and skills so that parents are able to manage the child's behavior effectively. SSTP comprises different levels based on increasing family complexity.
Study NCT02189629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD5789 (trifarotene)
Study NCT02446288 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMJ Next Generation
Study NCT02446288 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DSG Relaxer
Study NCT02333162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT02333162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT02333162 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMTMI
Study NCT02333162 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: Undergo IMTMI
Study NCT02333162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSCT
Study NCT02333162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSCT
Study NCT02333162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic BMT
Study NCT02333162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT02333162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO
Study NCT02333162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04136288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MoreNova
Description: Shockwave therapy delivered to the genital area with low dose shocks
Study NCT06238856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLIT™ Amikacin
Description: Amikacin administered via the Pari LC STAR™ nebulizer.
Study NCT06238856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Nebulized saline.
Study NCT01612364 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic sympathetic block
Description: Thoracic sympathetic block is sympathetic block of upper limb described by Leriche e Fontaine em 1925. The block is performed under radioscopic view, positioning the needle lateral the body of thoracic vertebra T3, where infuse anesthetic solution. The theoretical advantage over the stellate ganglion is its greater specificity and efficiency. Solution block: 5ml ropivacaine 0,75% + 5ml de triamcinolone 2%
Study NCT01612364 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic sympathetic block
Description: Thoracic sympathetic block is sympathetic block of upper limb described by Leriche e Fontaine em 1925. The block is performed under radioscopic view, positioning the needle lateral the body of thoracic vertebra T3, where infuse anesthetic solution. The theoretical advantage over the stellate ganglion is its greater specificity and efficiency. Solution block: 5ml ropivacaine 0,75% + 5ml de triamcinolone 2%
Study NCT02842242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYK-461
Study NCT02539758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ocular massage
Description: ocular massage could be applied over the globe over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.
Study NCT02539758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LenstarLS900
Description: observed changes of anterior chamber depth before and after ocular massage by LenstarLS900
Study NCT02539758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldmann tonometer
Description: observed changes of intraocular pressure before and after ocular massage by Goldmann tonometer
Study NCT03174899 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diffusion weighted magnetic resonance imaging
Description: All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient.
Study NCT03792984 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 (Cholecalciferol) (6000 IU/daily). PO for 8 weeks.
Study NCT03792984 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Calcium carbonate (1000 mg/daily). PO for 8 weeks.
Study NCT03792984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin (1500 mg/daily; the metformin dose was increased stepwise, starting with 500 mg once daily for the 1st week, 500 mg twice daily in the 2nd week, followed by 500 mg 3 times daily from the 3rd week onward). PO for 8 weeks.
Study NCT03792984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin (1500 mg/daily; the metformin dose was increased stepwise, starting with 500 mg once daily for the 1st week, 500 mg twice daily in the 2nd week, followed by 500 mg 3 times daily from the 3rd week onward). PO for 8 weeks.
Study NCT03792984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO for 8 weeks.
Study NCT01337687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.
Study NCT01337687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.
Study NCT00998764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bapineuzumab 0.5 mg/kg
Description: I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
Study NCT00057681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Description: Titrated until blood level is 1.1 to 1.3 mEq/L
Study NCT00057681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: Titrated until blood level is 111 to 125 ug/mL
Study NCT00057681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Titrated by weight until dose is 2.0 mg BID to 3.0 mg BID
Study NCT00625482 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OPV
Study NCT00625482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPV plus BCG
Study NCT03772314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Participants will received 100-400 milligrams (mg) per day of modafinil for 12 weeks.
Study NCT03772314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphetamine-Dextroamphetamine
Description: Participants will receive 10-40 mg/day of oral amphetamine salts for 12 weeks.
Study NCT03616587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with ribociclib
Description: Part K: AZD9833 in combination with ribociclib (± anastrozole) dose escalation
Study NCT03616587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with ribociclib
Description: Part L: AZD9833 in combination with ribociclib (± anastrozole) dose expansion
Study NCT03616587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with anastrozole
Description: Part M: AZD9833 in combination with anastrozole dose escalation
Study NCT03616587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with anastrozole
Description: Part N: AZD9833 in combination with anastrozole dose expansion
Study NCT00675961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Counseling Intervention (BCI)
Description: Two-tiered BCI characterized by both primary and secondary interventions. Primary BCI treatment format consists of 6 discussions delivered monthly in the first 6 months of standard TB treatment. 10-15 minutes long. Secondary BCI is delivered on a monthly basis while receiving TB treatment. 5-10 minutes long.
Study NCT00675961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Opioid antagonist, which decreases the pleasurable response to and craving for alcohol consumption. Oral; single daily dose of 50 mg per day for 6 months.
Study NCT00675961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BCI + Naltrexone
Description: Combination of the two previous interventions
Study NCT00675961 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Services provided by psychologists and narcologists (additions specialists) employed by the Tomsk Oblast TB Services.
Study NCT00280475 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole brain radiation therapy arm
Description: Whole brain radiation therapy arm
Study NCT00280475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Salvage stereotactic radiosurgery arm
Description: Salvage stereotactic radiosurgery arm
Study NCT00463151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rebamipide
Description: 0, 60, 150, 300mg of rebamipide per day for 6 weeks into colon
Study NCT00463151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rebamipide
Description: 0, 60, 150, 300mg of rebamipide per day for 6 weeks into colon
Study NCT01888562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib 45 mg daily for 4 weeks (4 weeks equal one cycle)
Study NCT04664335 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: if no Reply to questionnaire, telephone interview
Study NCT00807027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated T lymphocyte(Immuncell-LC)
Description: Efficacy/Effects: Removal of minimal residual cancer after removal of brain tumors and relapse prevention~Method of administration and quantity: Test Drug: Per 60kg of average adult body weight, administer 100mg that contains 109\~2x1010 lymphocytes for one hour intravenously. (Duration of administration can be controlled based on patient conditions)
Study NCT01899248 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Study NCT01899248 — intervention group
Intervention type: DRUG
Intervention: Desflurane
Study NCT02711722 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurally adjusted ventilatory assist
Description: Ventilation supported by NAVA~* Blood gas analysis~* Respiratory Parameters At the end of the study step Neuro-Ventilatory Efficiency and Neuro-Mechanical Efficiency are measured.
Study NCT02711722 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PScli1
Description: Pressure support set by clinicians prior to inclusion
Study NCT02711722 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PScli2
Description: Pressure support at the same level as prior to the study
Study NCT03436121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine is a medication approved by the US Food and Drug Administration (FDA) for anesthesia, sedation, and post-surgical pain treatment. It is not approved for emergency patients complaining of pain but is often used off-label. Ketamine may be useful for acute pain management and in treatment of depressed mood. The purpose of this study is to determine whether a single low dose of ketamine can relieve pain and reduce negative mood for 2 weeks after emergency department (ED) treatment.
Study NCT03436121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: In this study, all patients will also receive midazolam. Midazolam is a sedative that typically makes people feel relaxed and is intended to increase comfort with ketamine and reduce anxiety.
Study NCT03436121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: In this study, all patients will also receive midazolam. Midazolam is a sedative that typically makes people feel relaxed and is intended to increase comfort with ketamine and reduce anxiety.
Study NCT03436121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: In this study, patients in the active comparator group will receive midazolam first, then placebo. A placebo is an inactive solution that looks like the study drug, but contains no active ingredients.
Study NCT01235325 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phylloquinone (vitamin K1)
Description: 1000 mcg phylloquinone (vitamin K1) once daily for 12 months
Study NCT01235325 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo oil capsule
Study NCT02787538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: US-ANSWER-2 decision aid
Description: US-ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
Study NCT02787538 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group (Online medication guide)
Description: Standard online medication guide.
Study NCT04555629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced Cognitive Stimulation Therapy Hong Kong
Description: A modified version of Cognitive Stimulation Therapy for people with moderate to severe dementia translated and culturally adapted for the Hong Kong Chinese population.
Study NCT04018443 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: common carotid artery diameter measurement
Description: measurement of common carotid artery diameter will be carried out two times: the initial measurement (pre-infusion) which is followed by infusion of crystalloid solution (Ringer lactate) 30 ml/min till reaching a total infusion volume of 7 ml/kg body weight then another ultrasound measurement will be taken (prost-infusion). Between these sequential measurements, the patient position will not be changed. The percentage increase in CCA diameter will be calculated using the formula: \[(dia-mpost/dia-mpre) × 100\] - 100 \[11\].
Study NCT00936013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir
Description: 75mg p.o Bid for 5 days
Study NCT00936013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir and chinese medicinal herbs
Description: oseltamivir: 75mg p.o bid for 5 days chinese medicinal herbs:200ml p.o qid for 5 days
Study NCT00980707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (fluticasone)
Description: inhaled fluticasone 220 ug/bid